Abstract
Overexpression of the ATP-binding cassette subfamily B member 1 (ABCB1) transporter is a primary driver of multidrug resistance (MDR) in cancer, effectively pumping chemotherapeutic agents out of malignant cells. This study investigates the potential of RN486, a selective Bruton’s tyrosine kinase (BTK) inhibitor, to reverse this resistance. Our findings demonstrate that RN486 significantly enhances the efficacy of substrates like paclitaxel and doxorubicin in ABCB1-overexpressing cells. Mechanistically, RN486 inhibits the efflux activity of ABCB1 without altering its expression or localization. Molecular docking suggests RN486 interacts with both substrate-binding and inhibitor-binding sites, positioning it as a promising candidate for combination therapies to overcome MDR.
Introduction: The Challenge of Efflux Pumps
Multidrug resistance (MDR) remains a formidable barrier in clinical oncology. A major mechanism involves the overexpression of efflux transporters, most notably ABCB1 (P-glycoprotein). These pumps act as cellular "sump pumps," rapidly ejecting a wide range of structurally diverse chemotherapeutic drugs before they can reach their intracellular targets.
Recent research has explored repurposing kinase inhibitors as MDR reversal agents. Following the discovery that the BTK inhibitor ibrutinib can sensitize ABCB1-overexpressing cells, this study focuses on RN486, another potent and selective BTK inhibitor originally developed for autoimmune conditions.
Methods and Experimental Design
To evaluate RN486, researchers utilized two distinct cell line models:
- Drug-Selected Model: KB-C2 cells (resistant, overexpressing ABCB1) and their parental counterpart, KB-3-1.
- Genetically Engineered Model: HEK293 cells transfected with the ABCB1 gene (HEK293/ABCB1) and control cells (HEK293/pcDNA3.1).
The study employed MTT assays for cell viability, radioactive tracer assays using [3H]-paclitaxel to measure drug accumulation and efflux, and Western blotting/immunofluorescence to assess protein expression. Molecular docking simulations provided a structural basis for the observed inhibition.
Key Results: Restoring Chemosensitivity
A critical first step was determining the non-toxic concentration of RN486 to ensure that any observed sensitization was due to pump inhibition rather than direct toxicity.
Reversal of Resistance
In the presence of non-toxic concentrations of RN486 (up to 3 µM), the resistance of KB-C2 cells to paclitaxel was dramatically reversed. The resistance fold (RF) plummeted from 707.30 to 1.30, effectively restoring the sensitivity of the resistant cells to parental levels. Similar results were observed in the transfected HEK293/ABCB1 model.
Mechanism of Action
- Increased Drug Accumulation: RN486 treatment led to a significant increase in the intracellular concentration of [3H]-paclitaxel. In efflux assays, while control resistant cells pumped out 84% of the drug within two hours, RN486-treated cells retained nearly 50%.
- Functional Inhibition: Western blot and immunofluorescence analyses confirmed that RN486 does not decrease the total amount of ABCB1 protein or change its location on the cell membrane. Instead, it "clogs" the pump's function.
- ATPase Interaction: RN486 showed a concentration-dependent effect on ABCB1 ATPase activity, stimulating it at higher concentrations, which suggests it may compete with other substrates or act as an allosteric modulator.
- Molecular Docking: In silico models showed RN486 binding with high affinity to both the substrate-binding pocket and the inhibitor-binding site of human ABCB1, providing a structural explanation for its potent inhibitory effect.
Discussion and Clinical Implications
RN486 demonstrated superior potency compared to verapamil, a classic laboratory inhibitor of ABCB1. Importantly, RN486 did not affect the toxicity of cisplatin, a drug that is not an ABCB1 substrate, confirming the specificity of its action.
While these in vitro results are highly promising, further in vivo studies are required to evaluate the safety and efficacy of RN486-chemotherapy combinations in animal models. If successful, RN486 could be repurposed as a clinical reversal agent, offering a new strategy to overcome one of the most persistent challenges in cancer treatment.
Summary updated